T-Wave Oversensing in Patients With Left Bundle Branch Pacing: A Report of Three Cases and Review of Literature.

Pacing Clin ElectrophysiolMar 15, 2026 (epub)
Case ReportCardiologyOpen access

Fengqian Chen, Yuqing Wu, Dan Xu et al.

✦ AI-curated · Sources linked

Case in brief

The report describes three patients with T-wave oversensing (TWOS) after left bundle branch pacing (LBBP) at one hospital between 2020 and 2024. TWOS, a pacemaker sensing malfunction, may lead to inappropriate tachyarrhythmia detection and loss of pacing, potentially reducing the benefits of cardiac resynchronization therapy. The authors analyzed possible mechanisms and feasible solutions. The abstract does not provide patient-level presentation details, specific findings, interventions, or outcomes, so how the cases resolved cannot be stated.

What made this case unusual

The report highlights that TWOS after LBBP may be detected immediately after implantation or only after a relatively long interval, complicating recognition.

Diagnostic / clinical pearl

Consider TWOS when a patient with LBBP has inappropriate tachyarrhythmia detection or loss of pacing; it may emerge soon after the procedure or later.

Why it matters

The authors emphasize timely attention to TWOS because it can interfere with pacing and attenuate potential CRT benefits.

Source

PubMed · PMID 41834242Free full text on PubMed Central

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.